WallStSmart

Broadcom Inc (AVGO)vsAstraZeneca PLC (AZN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Broadcom Inc generates 13% more annual revenue ($68.28B vs $60.44B). AVGO leads profitability with a 36.6% profit margin vs 17.2%. AVGO appears more attractively valued with a PEG of 0.93. AVGO earns a higher WallStSmart Score of 78/100 (B+).

AVGO

Strong Buy

78

out of 100

Grade: B+

Growth: 9.3Profit: 9.5Value: 5.0Quality: 6.5
Piotroski: 6/9Altman Z: 1.59

AZN

Buy

62

out of 100

Grade: C+

Growth: 6.0Profit: 8.5Value: 5.3Quality: 5.0
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AVGO.

AZNUndervalued (+6.6%)

Margin of Safety

+6.6%

Fair Value

$220.34

Current Price

$182.85

$37.49 discount

UndervaluedFair: $220.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVGO6 strengths · Avg: 9.3/10
Market CapQuality
$2.04T10/10

Mega-cap, among the largest globally

Return on EquityProfitability
33.4%10/10

Every $100 of equity generates 33 in profit

Profit MarginProfitability
36.6%10/10

Keeps 37 of every $100 in revenue as profit

Operating MarginProfitability
44.9%10/10

Strong operational efficiency at 44.9%

PEG RatioValuation
0.938/10

Growing faster than its price suggests

Revenue GrowthGrowth
29.5%8/10

Revenue surging 29.5% year-over-year

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$286.68B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
23.5%9/10

Every $100 of equity generates 24 in profit

Operating MarginProfitability
28.2%8/10

Strong operational efficiency at 28.2%

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

Areas to Watch

AVGO3 concerns · Avg: 2.7/10
Altman Z-ScoreHealth
1.594/10

Distress zone — elevated risk

P/E RatioValuation
84.0x2/10

Premium valuation, high expectations priced in

Price/BookValuation
25.5x2/10

Trading at 25.5x book value

AZN3 concerns · Avg: 3.3/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
27.9x4/10

Moderate valuation

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AVGO

The strongest argument for AVGO centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 36.6% and operating margin at 44.9%. Revenue growth of 29.5% demonstrates continued momentum.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.

Bear Case : AVGO

The primary concerns for AVGO are Altman Z-Score, P/E Ratio, Price/Book. A P/E of 84.0x leaves little room for execution misses.

Bear Case : AZN

The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.

Key Dynamics to Monitor

AVGO profiles as a growth stock while AZN is a mature play — different risk/reward profiles.

AVGO carries more volatility with a beta of 1.44 — expect wider price swings.

AVGO is growing revenue faster at 29.5% — sustainability is the question.

AVGO generates stronger free cash flow (8.0B), providing more financial flexibility.

Bottom Line

AVGO scores higher overall (78/100 vs 62/100), backed by strong 36.6% margins and 29.5% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Broadcom Inc

TECHNOLOGY · SEMICONDUCTORS · USA

Broadcom Inc. is an American designer, developer, manufacturer and global supplier of a wide range of semiconductor and infrastructure software products. Broadcom's product offerings serve the data center, networking, software, broadband, wireless, and storage and industrial markets.

Visit Website →

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?